A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non–Small Cell Lung Cancer

Published:2020-03-19 Issue:14 Volume:26 Page:3525-3536
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Cascone Tina,Sepesi Boris,Lin Heather Y.,Kalhor Neda,Parra Edwin R.^ORCID,Jiang Mei,Godoy Myrna C.B.,Zhang Jianjun,Fossella Frank V.,Tsao Anne S.^ORCID,Lam Vincent K.,Lu Charles,Mott Frank E.,Simon George R.,Antonoff Mara B.,Mehran Reza J.,Rice David C.,Behrens Carmen,Weissferdt Annikka,Moran Cesar,Vaporciyan Ara A.,Lee J. Jack,Swisher Stephen G.^ORCID,Gibbons Don L.,Wistuba Ignacio I.,William William N.^ORCID,Heymach John V.^ORCID

Funder

Boehringer Ingelheim

Lung SPORE grant 5

Cancer Center Support Grant

American Society of Clinical Oncology

The University of Texas MD Anderson Cancer Center Lung Cancer Moon Shot Program

The University of Texas MD Anderson Cancer Center CG Johnson Foundation Advanced Scholar Program

The University of Texas MD Anderson Cancer Center Khalifa Scholar Program

The University of Texas MD Anderson Cancer Center Physician Scientist Program

T.J. Martell Foundation

Bruton Endowed Chair in Tumor Biology Funds

The Bob Mayberry Foundation